Testosterone therapy works, but it only works safely when the labs get tracked on a schedule — not just once at baseline and then never again. This guide breaks down exactly which markers to order, when to draw them, and what the numbers actually mean once you're on treatment.
- Seven markers matter: total testosterone, free testosterone, sensitive estradiol, hematocrit, PSA, a comprehensive metabolic panel, and a lipid panel
- Draw a full baseline before the first dose, repeat at 6-8 weeks, then every 6-12 months once stable
- Hematocrit above roughly 54% and a PSA rise over 1.4 ng/mL in 12 months are the two thresholds that force a protocol change
- A sensitive (not standard) estradiol assay is required to read male-range results accurately
- Free testosterone and SHBG explain persistent symptoms even when total testosterone looks normal
- Trend lines across multiple draws matter more than any single lab value
TL;DR
Testosterone therapy labs to monitor in 2026 come down to seven markers: total testosterone, free testosterone, estradiol (sensitive assay), hematocrit, PSA, a comprehensive metabolic panel, and a lipid panel. Baseline draws happen before the first dose, follow-up draws happen at 6-8 weeks after starting or adjusting dose, then every 6-12 months once stable. Verdict: skip the therapy entirely if a clinic won't commit to hematocrit and PSA monitoring — untreated polycythemia and unmonitored PSA trends are the two things that turn testosterone therapy from a benefit into a liability. GoodLife Health builds these draws into every testosterone protocol rather than leaving it to the patient to remember.
Why this matters
Testosterone therapy changes more than energy and libido — it changes red blood cell mass, estrogen conversion, and prostate-specific antigen trends, and none of those show symptoms until they've gone too far. Hematocrit above roughly 54% raises clotting risk substantially, and it climbs silently over months, not days. A PSA jump of more than 1.4 ng/mL over 12 months on therapy is a standard trigger for urology referral, per widely used endocrine society guidance — but that only gets caught if someone is actually drawing PSA on a schedule. In 2026, at-home TRT vendors that skip lab monitoring to cut costs are still common, and it's the single biggest red flag to screen out before you commit to a protocol. Baseline labs before starting hormone therapy set the reference point every later result gets measured against — skip that step and you're flying blind by month six.
A PSA jump of more than 1.4 ng/mL over 12 months on therapy is a standard trigger for urology referral, per widely used endocrine society guidance — but that only gets caught if someone is actually drawing PSA on a schedule.
What you'll need
- A baseline blood draw before the first testosterone dose — fasting, morning draw preferred since testosterone peaks earlier in the day
- A clinician who reviews results and adjusts dose, not just a portal that emails you a PDF
- A repeat draw scheduled at 6-8 weeks post-start or post-dose-change
- A recurring draw cadence at 6-12 months once levels stabilize
- Access to your own lab history so you can track trend lines, not single snapshots
The steps
1. Order the full baseline panel before the first dose
This establishes what normal looks like for you specifically, since reference ranges are population averages, not individual targets. The baseline panel should include total testosterone, free testosterone, sex hormone-binding globulin (SHBG), estradiol via sensitive assay, hematocrit and hemoglobin, PSA (for men over 40 or with prostate risk factors), a comprehensive metabolic panel, and a fasting lipid panel. Total testosterone reference ranges typically run 300-1000 ng/dL, but symptoms matter as much as the number — a man at 350 ng/dL with fatigue and low libido is a different case than one at 350 ng/dL with no symptoms at all. Common mistake: drawing testosterone in the afternoon, when levels can read 20-30% lower than a morning draw and trigger an unnecessary diagnosis.
2. Draw the follow-up panel at 6-8 weeks
This is the window where testosterone therapy — whether injections, gels, or pellets — reaches a stable state worth measuring. Draw total and free testosterone, estradiol, and hematocrit again at this point to confirm the starting dose is landing in a therapeutic range without pushing hematocrit or estradiol too high. For injectable therapy, timing matters: a trough level (drawn right before the next dose) tells you the low point, while a mid-cycle draw tells you the peak — mixing these up produces confusing, non-comparable numbers over time. Common mistake: switching labs or draw timing between baseline and follow-up, which makes trend comparison meaningless.
3. Check hematocrit every time testosterone gets checked
Hematocrit rises on testosterone therapy because the hormone stimulates red blood cell production, and it's the marker most likely to force a dose change or pause. A hematocrit above roughly 52-54% is the commonly used threshold where clinicians start reducing dose, spacing out injections, or recommending therapeutic phlebotomy. This isn't a once-a-year check — it needs to run alongside every testosterone draw, especially in the first six months of therapy. Common mistake: treating hematocrit as optional because it feels unrelated to the reason you started treatment.
A hematocrit above roughly 52-54% is the commonly used threshold where clinicians start reducing dose, spacing out injections, or recommending therapeutic phlebotomy. This isn't a once-a-year check — it needs to run alongside every testosterone draw, especially in the first six months of therapy.
4. Track estradiol with a sensitive assay, not a standard one
Testosterone converts to estradiol via aromatase, and men on therapy can see estradiol climb into ranges that cause water retention, mood swings, or breast tenderness if left unchecked. Standard estradiol assays built for female physiology often can't detect accurately in the lower ranges typical for men, so the sensitive (or ultrasensitive) assay matters here. A commonly cited target range for men on TRT sits around 20-40 pg/mL, though the right number depends on symptoms as much as the lab value. Common mistake: treating any estradiol elevation as an automatic reason to add an aromatase inhibitor — over-suppression causes its own problems, including joint pain and low libido.
5. Draw PSA before starting and then annually
PSA monitoring exists to catch prostate changes early, not because testosterone therapy is proven to cause prostate cancer — current evidence doesn't support that direct link. Still, a PSA increase of more than 1.4 ng/mL within 12 months on therapy, or an absolute PSA above 4.0 ng/mL, are standard thresholds that prompt a urology referral in most treatment protocols. This draw matters most for men over 40 or with a family history of prostate cancer. Common mistake: skipping PSA because a patient feels fine — PSA trends move independently of symptoms.
6. Run a lipid panel and metabolic panel alongside hormone labs
Testosterone therapy interacts with metabolic markers in both directions — some men see improved insulin sensitivity and reduced visceral fat, others see shifts in HDL cholesterol. A comprehensive metabolic panel run alongside hormone labs catches liver enzyme changes and kidney function shifts that matter for dose safety, particularly for men also managing metabolic syndrome or starting GLP-1 therapy concurrently. Common mistake: treating hormone labs and metabolic labs as separate appointments months apart, when drawing them together saves a stick and gives a fuller picture.
7. Log every result and watch the trend line, not the single number
One lab value tells you where you are; three consecutive draws tell you where you're headed. A hematocrit that moved from 46% to 49% to 53% over three draws is a different clinical picture than a single 53% reading with no history. GoodLife Health patients get lab history stored and reviewed by a clinician at each draw specifically so dose adjustments respond to trend, not panic over one number. Common mistake: only remembering the most recent lab and losing the pattern that actually predicts risk.
One lab value tells you where you are; three consecutive draws tell you where you're headed.
Troubleshooting
Troubleshooting quick reference
matched to likely cause and action
| Issue | Likely explanation | Action |
|---|---|---|
| Testosterone level looks normal but symptoms haven't improved | Free testosterone and SHBG matter more than total testosterone in this scenario | A high SHBG can bind up available hormone even when the total number looks fine |
| Estradiol reads unusually high | The lab may have used a standard assay instead of a sensitive one | Confirm assay type before assuming the result is accurate |
| Hematocrit crossed 54% | Red blood cell mass has risen to a risk threshold | Expect a dose reduction, injection frequency change, or referral for therapeutic phlebotomy |
| PSA rose more than 1 ng/mL between draws | Prostate marker moved outside normal drift | Warrants a repeat draw and possible urology referral before continuing the same dose |
| Labs were drawn at inconsistent times of day | Testosterone naturally peaks earlier in the day | Request morning draws going forward and flag prior results as non-comparable |
| No baseline was drawn before starting therapy | There's no reference point for later results | Get one now — a late baseline is still more useful than none at all |
Tools and resources
- A clinician-reviewed hormone protocol, not a self-service prescription pad
- Low testosterone symptoms in men — what labs actually show for matching symptoms to specific markers before treatment starts
- A concurrent metabolic check if you're also managing weight — see how to start medical weight loss with a doctor for how the two protocols run together
- A shared lab portal so results land with your clinician and with you at the same time
- A recurring calendar reminder for the 6-8 week and 6-12 month draw windows
What to do next
Once baseline and follow-up labs are in hand, the next step is matching the numbers to a dosing format — injection, gel, or pellet — that fits the trend lines you're seeing rather than defaulting to whatever a clinic sells by default.
FAQ
What labs do you need before starting testosterone therapy? Baseline labs include total and free testosterone, SHBG, sensitive estradiol, hematocrit, PSA (for men over 40), a comprehensive metabolic panel, and a lipid panel, drawn before the first dose.
How often should testosterone levels get checked once on therapy? Most protocols draw follow-up labs at 6-8 weeks after starting or changing dose, then every 6-12 months once levels stabilize.
Is hematocrit really that important on TRT? Yes — hematocrit above roughly 54% raises clotting risk and is one of the most common reasons for a dose reduction or pause in testosterone therapy.
Does testosterone therapy cause prostate cancer? Current evidence doesn't show a direct causal link, but PSA still gets monitored because a rise of more than 1.4 ng/mL in 12 months warrants further evaluation.
Why does estradiol matter for men on testosterone therapy? Testosterone converts to estradiol via aromatase, and unmonitored elevation can cause water retention and mood changes — a sensitive assay is needed to read male-range estradiol accurately.
Can testosterone therapy affect cholesterol? It can shift HDL and other lipid markers in either direction, which is why a lipid panel gets drawn alongside hormone labs rather than as a separate annual check.
What if testosterone comes back normal but symptoms persist? Check free testosterone and SHBG specifically — a high SHBG can leave less bioavailable hormone even when total testosterone looks adequate.
Do labs differ between injections and pellets? Draw timing matters more than the delivery method — trough versus mid-cycle draws for injections, and a consistent point in the pellet cycle for pellet therapy, so results stay comparable across the year.
One last thing
The lab that gets skipped most often isn't testosterone — it's PSA, because patients assume it's only relevant once symptoms show up. By the time a prostate issue produces symptoms, the annual PSA trend already missed its window to catch it early; that's the one draw worth insisting on even if a clinic tries to bundle it out to save cost in 2026.
Related guides
References
- Testosterone Therapy in Men with Hypogonadism: An Endocrine Society Clinical Practice Guideline. 2018. doi.org/10.1210/jc.2018-00229